Review




Structured Review

Karius Inc mcfdna seq
Mcfdna Seq, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/mcfdna+seq/pm41780551-70-29-42
Average 86 stars, based on 1 article reviews
mcfdna seq - by Bioz Stars, 2026-10
86/100 stars

Images

Related Articles

other:

Article Title: Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-free DNA
Article Snippet: We conducted plasma mcfDNA-Seq with the Karius Test® [Karius Inc., Redwood City, CA] and classified the derived metagenomic sequences as human (hcfDNA) vs. microbial (mcfDNA).

Article Title: Direct Testing of Blood Samples to Diagnose Bloodstream Infections.
Article Snippet: Bloodstream infection (BSI) is a critical condition with extremely high mortality.. Rapid and accurate diagnosis is crucial for effective treatment.. The traditional blood culture (BC) method has issues, such as long testing times and limited sensitivity, making it challenging to meet the need for timely diagnosis.

Article Title: Association for Molecular Pathology 2020 Annual Meeting Abstracts
Article Snippet: G01.. Development and Validation of a High-Throughput NextGeneration Sequencing Assay from Buccal Cell DNA as a CostEffective Screening Method for Celiac Genetic Risk S. Gunn1, A. Bhandari2, S. Verma2, H. Gandhi3, D. Rolle3, L. Lim2, P. Cotter2, M. Moore2 1ResearchDx, San Antonio, TX; 2ResearchDx, Irvine, CA; 3PacificDx, Irvine, CA.. Introduction: An estimated 1% of the global population has been diagnosed with celiac disease (CD), an autoimmune condition triggered by dietary gluten in individuals who carry HLA-DQ2 and/or HLA-DQ8 (DQ2/DQ8) celiac risk alleles.

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: This study was additionally supported by the National Cancer Institute (R25CA23944; AB), by a St Jude Children’s Research Hospital Comprehensive Cancer Center Developmental Funds Award (JW, CG, and PT), and by non-financial support from Karius, which provided mcfDNA-Seq testing.

Article Title: 669. Metagenomic Plasma Microbial Cell Free DNA-Sequencing Assists in Diagnosis of Infections and Critical Antimicrobial Changes in Immunocompromised Hosts
Article Snippet: Metagenomic next-generation sequencing of plasma cell-free DNA (Karius®) (plasma mcf-DNA-seq) is a noninvasive approach that may have a unique role for the diagnosis of infectious complications in immunocompromised patients.

Article Title: Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-free DNA
Article Snippet: Karius McfDna-Seq , Karius Inc. , N/A.

Article Title: The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches
Article Snippet: There are a few commercially available NGS platforms that detect cell-free DNA (mcf-DNA-seq) from plasma (Karius, Redwood, CA, USA), DNA and RNA from cerebrospinal fluid (University of California, USA) and respiratory secretions (IDbyDNA, Salt Lake City, UT, USA) to diagnose fungal pathogens (in addition to bacterial and viral pathogens) [ ].

Infection:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

Control:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

Concentration Assay:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..

Clinical Proteomics:

Article Title: Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study.
Article Snippet: .. Bloodstream infection-related samples (collected between 7 days before and 1 day after bloodstream infection onset), along with up to two control samples per episode from the same cohort, underwent mcfDNA-Seq in a Clinical Laboratory Improvement Amendments-accredited and College of American Pathologists-accredited laboratory (Karius, Redwood City, CA, USA), and the concentration of microbial DNA fragments for each organism identified using a proprietary reference-genome database was reported in molecules per μL of plasma (appendix pp 2–3). ..



Similar Products

99
Plasmidsaurus bulk rna sequencing
Bulk Rna Sequencing, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/RNA-Seq/10__1158_slash_0008___5472__can___26___0823-148-0-5
Average 99 stars, based on 1 article reviews
bulk rna sequencing - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

92
Integrated DNA Technologies xgen methyl-seq lib prep
Xgen Methyl Seq Lib Prep, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/xGen+Methyl-Seq+Lib+Prep/custom%4010009860%4042753031
Average 92 stars, based on 1 article reviews
xgen methyl-seq lib prep - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier

86
Thermo Fisher ion total rna seq kit v2
Ion Total Rna Seq Kit V2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/nct04488614-6-19-24
Average 86 stars, based on 1 article reviews
ion total rna seq kit v2 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

86
Karius Inc mcfdna seq
Mcfdna Seq, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/mcfdna+seq/pm41780551-70-29-42
Average 86 stars, based on 1 article reviews
mcfdna seq - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

99
Plasmidsaurus bulk rna seq
( A ) <t>Bulk</t> <t>RNA-seq</t> data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.
Bulk Rna Seq, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/RNA-Seq/pmc13588199-355-7-5
Average 99 stars, based on 1 article reviews
bulk rna seq - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

99
Plasmidsaurus rna sequencing
( A ) <t>Bulk</t> <t>RNA-seq</t> data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.
Rna Sequencing, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/RNA-Seq/pm42748925-806-11-9
Average 99 stars, based on 1 article reviews
rna sequencing - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

99
Complete Genomics Inc stereo-cite proteo-transcriptomics set
( A ) <t>Bulk</t> <t>RNA-seq</t> data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.
Stereo Cite Proteo Transcriptomics Set, supplied by Complete Genomics Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/seq/Stereo-CITE+Proteo-Transcriptomics+Set/custom%40211pt11114%4010%2E1096%2Ffj%2E202502942rrr
Average 99 stars, based on 1 article reviews
stereo-cite proteo-transcriptomics set - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


( A ) Bulk RNA-seq data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.

Journal: Science Advances

Article Title: Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models

doi: 10.1126/sciadv.aef7756

Figure Lengend Snippet: ( A ) Bulk RNA-seq data are used to translate between clinical samples (in vivo) with phenotypic annotations and an MPS model of disease (in vitro). ( B ) The MASLD score (MAS) and fibrosis stage are clinically relevant metrics of disease that correlate and need to be modeled jointly. ( C ) A PLSR model predicts both phenotypes from bulk transcriptomics and performs significantly better in 10-fold cross-validation than random or shuffled models. For all comparisons, a two-sided unpaired Wilcoxon test was used. In all box plots, the centerline denotes the median, the bounds of the box denote the first and third quantiles, and the whiskers denote points not being further from the median than 1.5 × interquartile range. ( D ) The PLSR model with eight LVs fits the full clinical dataset well and achieves good correlations with the measured phenotypes. ( E ) Qualitative trends in the phenotypic scores are visible when projecting the clinical data onto the first two LVs of the PLSR model.

Article Snippet: Purified RNA was sent to Plasmidsaurus for bulk RNA-seq using the Illumina sequencing technology.

Techniques: RNA Sequencing, In Vivo, In Vitro, Transcriptomics, Biomarker Discovery

( A ) Schematic of validation liver triculture spheroid experiments. Hepatocytes, Kupffer cells, and hepatic stellate cells were seeded in a 10:1:1 ratio in alginate wells and cultured for 11 days. Treatments were initiated on day 3 (D3) and replenished with each medium change. ( B and C ) Quantification of spheroid phenotypes shows that TGFβ1 (10 ng/ml) decreased steatosis, as measured by normalized BODIPY signal (B), while increasing fibrosis, measured by α-SMA in vimentin-positive areas (C). Cotreatment with IFN-α (1000 U/ml) reduced lipid content further and restored α-SMA to baseline expression. a.u., arbitrary units. ( D ) Bulk RNA-seq performed on parallel spheroid cultures reveals strong transcriptional differences associated with the experimental treatments, as evidenced by PCA. ( E ) Pathway activity inference confirms a TGFβ signature associated with PC1 and a JAK-STAT signature associated with PC2. ( F ) Projection of the gene expression data onto TC1 and extra LV 1 preserves clustering by experimental condition. Imaging data are presented as a ratio normalized to the median of the control group. Each point represents an individual spheroid. In all panels, asterisks indicate statistical significance level defined as follows: **** P ≤ 10 –4 , *** P ≤ 10 –3 , and ns for P > 0.05.

Journal: Science Advances

Article Title: Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models

doi: 10.1126/sciadv.aef7756

Figure Lengend Snippet: ( A ) Schematic of validation liver triculture spheroid experiments. Hepatocytes, Kupffer cells, and hepatic stellate cells were seeded in a 10:1:1 ratio in alginate wells and cultured for 11 days. Treatments were initiated on day 3 (D3) and replenished with each medium change. ( B and C ) Quantification of spheroid phenotypes shows that TGFβ1 (10 ng/ml) decreased steatosis, as measured by normalized BODIPY signal (B), while increasing fibrosis, measured by α-SMA in vimentin-positive areas (C). Cotreatment with IFN-α (1000 U/ml) reduced lipid content further and restored α-SMA to baseline expression. a.u., arbitrary units. ( D ) Bulk RNA-seq performed on parallel spheroid cultures reveals strong transcriptional differences associated with the experimental treatments, as evidenced by PCA. ( E ) Pathway activity inference confirms a TGFβ signature associated with PC1 and a JAK-STAT signature associated with PC2. ( F ) Projection of the gene expression data onto TC1 and extra LV 1 preserves clustering by experimental condition. Imaging data are presented as a ratio normalized to the median of the control group. Each point represents an individual spheroid. In all panels, asterisks indicate statistical significance level defined as follows: **** P ≤ 10 –4 , *** P ≤ 10 –3 , and ns for P > 0.05.

Article Snippet: Purified RNA was sent to Plasmidsaurus for bulk RNA-seq using the Illumina sequencing technology.

Techniques: Biomarker Discovery, Cell Culture, Expressing, RNA Sequencing, Activity Assay, Gene Expression, Imaging, Control